SEK 75.6
(-1.05%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 133.8 Million SEK | 30.31% |
2022 | 102.67 Million SEK | 36.71% |
2021 | 75.1 Million SEK | 20.4% |
2020 | 62.37 Million SEK | -4.52% |
2019 | 65.33 Million SEK | 29.99% |
2018 | 50.25 Million SEK | 56.54% |
2017 | 32.1 Million SEK | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 34.1 Million SEK | 3.08% |
2024 Q1 | 33.08 Million SEK | -8.47% |
2023 Q3 | 33.81 Million SEK | 3.87% |
2023 FY | 133.8 Million SEK | 30.31% |
2023 Q1 | 31.27 Million SEK | 54.89% |
2023 Q2 | 32.55 Million SEK | 4.09% |
2023 Q4 | 36.14 Million SEK | 6.87% |
2022 Q1 | 25.22 Million SEK | 27.21% |
2022 Q4 | 20.19 Million SEK | -30.71% |
2022 Q3 | 29.14 Million SEK | 3.65% |
2022 Q2 | 28.11 Million SEK | 11.46% |
2022 FY | 102.67 Million SEK | 36.71% |
2021 Q1 | 17.01 Million SEK | 3.75% |
2021 Q2 | 18.4 Million SEK | 8.15% |
2021 Q3 | 19.85 Million SEK | 7.92% |
2021 Q4 | 19.82 Million SEK | -0.15% |
2021 FY | 75.1 Million SEK | 20.4% |
2020 Q1 | 14.33 Million SEK | -29.57% |
2020 Q3 | 13.88 Million SEK | 2.87% |
2020 Q4 | 16.4 Million SEK | 18.1% |
2020 FY | 62.37 Million SEK | -4.52% |
2020 Q2 | 13.49 Million SEK | -5.86% |
2019 Q4 | 20.35 Million SEK | 31.95% |
2019 FY | 65.33 Million SEK | 29.99% |
2019 Q1 | 14.08 Million SEK | -0.82% |
2019 Q2 | 15.2 Million SEK | 8.0% |
2019 Q3 | 15.42 Million SEK | 1.45% |
2018 Q3 | 13.32 Million SEK | 18.68% |
2018 Q4 | 14.19 Million SEK | 6.59% |
2018 Q2 | 11.22 Million SEK | -2.51% |
2018 FY | 50.25 Million SEK | 56.54% |
2018 Q1 | 11.51 Million SEK | -1.82% |
2017 FY | 32.1 Million SEK | 0.0% |
2017 Q1 | 333 Thousand SEK | 0.0% |
2017 Q2 | 5.79 Million SEK | 1639.64% |
2017 Q3 | 10.55 Million SEK | 82.27% |
2017 Q4 | 11.72 Million SEK | 11.06% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Acarix AB (publ) | 82.85 Million SEK | -61.497% |
ADDvise Group AB (publ) | 611.8 Million SEK | 78.13% |
ADDvise Group AB (publ) | 611.8 Million SEK | 78.13% |
Arcoma AB | 53.25 Million SEK | -151.258% |
Bactiguard Holding AB (publ) | 4.96 Million SEK | -2592.695% |
BICO Group AB (publ) | 2.84 Billion SEK | 95.303% |
Boule Diagnostics AB (publ) | 210.44 Million SEK | 36.42% |
CellaVision AB (publ) | 295.99 Million SEK | 54.796% |
Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -94.11% |
Chordate Medical Holding AB (publ) | 1.3 Million SEK | -10120.114% |
C-Rad AB (publ) | 3.8 Million SEK | -3421.053% |
Duearity AB (publ) | 21.58 Million SEK | -519.875% |
Dignitana AB (publ) | 74.73 Million SEK | -79.03% |
Episurf Medical AB (publ) | 2.7 Million SEK | -4855.556% |
Getinge AB (publ) | 10.75 Billion SEK | 98.756% |
Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -634.013% |
Iconovo AB (publ) | 63.35 Million SEK | -111.193% |
Integrum AB (publ) | 90.57 Million SEK | -47.729% |
Luxbright AB (publ) | 23.09 Million SEK | -479.459% |
Mentice AB (publ) | 237.06 Million SEK | 43.559% |
OssDsign AB (publ) | 175.6 Million SEK | 23.805% |
Promimic AB (publ) | 48.55 Million SEK | -175.581% |
Qlife Holding AB (publ) | 162.38 Million SEK | 17.603% |
SciBase Holding AB (publ) | 69.97 Million SEK | -91.208% |
ScandiDos AB (publ) | 61.03 Million SEK | -119.208% |
Sectra AB (publ) | 39.06 Million SEK | -242.524% |
Sedana Medical AB (publ) | 174.52 Million SEK | 23.336% |
Senzime AB (publ) | 141.51 Million SEK | 5.453% |
SpectraCure AB (publ) | 12.12 Million SEK | -1003.232% |
Stille AB | 87.21 Million SEK | -53.407% |
Vitrolife AB (publ) | 5.56 Billion SEK | 97.597% |
Xvivo Perfusion AB (publ) | 440.92 Million SEK | 69.655% |